Nonetheless it is worth to mention that high levels of (endogenous) 21-deoxysteroids have been found in patients with Cushing’s disease [117] and hypertension [118] and in vitro studies showed that they act as weak agonist on glucocorticoid receptors (GR) [119] and may transactivate the mineralocorticoid receptor (MR) although to a lesser extent than aldosterone and fludrocortisone [120]. This evidence concerns the gene NR3C2 and Hypertension.